Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aeglea Biothera (AGLE)

Aeglea Biothera (AGLE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,527
  • Shares Outstanding, K 61,511
  • Annual Sales, $ 18,740 K
  • Annual Income, $ -65,800 K
  • 60-Month Beta 1.91
  • Price/Sales 4.00
  • Price/Cash Flow N/A
  • Price/Book 1.11
Trade AGLE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.14
  • Most Recent Earnings -0.19 on 11/03/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 639.93% ( +3.05%)
  • Historical Volatility 358.18%
  • IV Percentile 99%
  • IV Rank 78.66%
  • IV High 804.69% on 06/17/22
  • IV Low 32.52% on 03/11/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 74
  • Volume Avg (30-Day) 163
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 3,757
  • Open Int (30-Day) 1,638

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.20
  • Number of Estimates 3
  • High Estimate -0.18
  • Low Estimate -0.22
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +35.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3911 +8.21%
on 11/30/22
1.5600 -72.87%
on 11/10/22
-0.6868 (-61.87%)
since 11/01/22
3-Month
0.3911 +8.21%
on 11/30/22
1.5600 -72.87%
on 11/10/22
-0.1085 (-20.41%)
since 09/01/22
52-Week
0.3720 +13.76%
on 08/02/22
6.2600 -93.24%
on 12/02/21
-5.5568 (-92.92%)
since 12/01/21

Most Recent Stories

More News
BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics

BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs targeting immune modulation in cancer and other diseases. Stock up.

AGLE : 0.4232 (+1.98%)
ASLN : 0.5572 (+1.36%)
BNTX : 169.47 (+1.47%)
IMCR : 59.98 (-4.51%)
Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

AGLE : 0.4232 (+1.98%)
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

AGLE : 0.4232 (+1.98%)
Seagen (SGEN) Adcetris Label Expansion OK'd, New CEO Named

The FDA approves Seagen's (SGEN) Adcetris for a new indication, treating pediatric patients with previously untreated high-risk Hodgkin lymphoma. The company also appoints a new CEO.

AMRN : 1.1900 (+3.48%)
SGEN : 121.02 (-0.30%)
AGLE : 0.4232 (+1.98%)
ASLN : 0.5572 (+1.36%)
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates

Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AGLE : 0.4232 (+1.98%)
FOLD : 12.28 (+1.49%)
Aeglea: Q3 Earnings Snapshot

Aeglea: Q3 Earnings Snapshot

AGLE : 0.4232 (+1.98%)
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

AGLE : 0.4232 (+1.98%)
Seres Therapeutics (MCRB) Reports Q3 Loss, Lags Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MCRB : 6.67 (+2.62%)
AGLE : 0.4232 (+1.98%)
Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers

Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.

GILD : 87.90 (+0.08%)
MGNX : 6.92 (+7.62%)
AGLE : 0.4232 (+1.98%)
AKRO : 45.69 (-1.74%)
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition

AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.

ABBV : 161.63 (+0.28%)
AGLE : 0.4232 (+1.98%)
AKRO : 45.69 (-1.74%)
ORIC : 4.04 (+12.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical...

See More

Key Turning Points

3rd Resistance Point 0.4861
2nd Resistance Point 0.4665
1st Resistance Point 0.4448
Last Price 0.4232
1st Support Level 0.4035
2nd Support Level 0.3839
3rd Support Level 0.3622

See More

52-Week High 6.2600
Fibonacci 61.8% 4.0108
Fibonacci 50% 3.3160
Fibonacci 38.2% 2.6212
Last Price 0.4232
52-Week Low 0.3720

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar